The UK and US have forged a important bilateral deal that will ensure no import taxes on British drug exports going into the US market.
Key Provisions of the Deal
In exchange for the tariff guarantee, the UK has committed to raise funding on drugs through the NHS. This move ensures that duties on these vital goods will be held at zero for a period of the next three years.
This deal comes after recent statements to dramatically increase import taxes on patented drug imports, with increases mentioned up to 100%.
"This deal with the UK bolsters the international landscape for cutting-edge drugs and brings long-overdue balance to American-British medicine commerce," a release declared.
Trade Importance
Pharmaceuticals constitute one of the the United Kingdom's biggest exports to the America, which is easily the largest market for large British pharmaceutical firms.
Export figures show that in the year prior to September, the UK sold medicines totaling £11.1bn to the US. This figure made up 17.4% of British export trade in that period.
"This deal secures work, increases capital expenditure and paves the way for the UK to emerge as a global hub for medical research," a minister stated.
Key UK Commitments
The deal includes several specific pledges from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the cost ceiling at which it considers new medicines to be unaffordable by 25%.
- Boosted Medicine Funding: There is a aim to double overall NHS spending on medicines from 0.3 percent of the national economy to 0.6 percent over the coming ten years.
- Payback Limit: The sum drug companies must pay back to the NHS to prevent overspending will be restricted at fifteen percent. Last year, rebates topped twenty percent.
Broader Context
This agreement takes place against a long-running dispute between the drug companies and the British authorities over drug pricing and approval rates.
The disagreement were heightened by arguments that US patients were paying several times more for the same drugs than people in the other developed nations.
In recent months, several major pharmaceutical investments in the UK have been delayed or cancelled, while multi-billion-dollar investments have been directed toward American operations.
One official publicly accepted that the NHS had to invest a greater share on medicines, noting that its budget allocation on drugs had shrunk as a percentage of its overall budget over the previous ten-year period.
